The National Institute on Alcohol Abuse and Alcoholism opened two Phase 1 trials in the same cycle, both repurposing approved drugs with mechanisms from outside addiction medicine, both built to probe the brain’s dopamine reward circuitry in alcohol use disorder. One tests tirzepatide, the dual GIP and GLP-1 agonist approved for diabetes and obesity. The other tests suvorexant, an orexin-receptor antagonist approved for insomnia. It is the addiction version of a pattern the desk has been tracking, a stuck indication being revived through federal repurposing of existing drugs rather than new molecules, and it carries one difference that separates it from the others.
The stalled baseline
Alcohol use disorder is a leading cause of disease and death, and its pharmacology is thin and old. Three drugs are approved for it, naltrexone, acamprosate, and disulfiram, all decades old, all modestly effective, and all badly underused in practice. As with obsessive-compulsive disorder, which the desk covered as a parallel case, AUD is an indication where the science stalled and the commercial incentive stayed weak, leaving a large and underserved population with few good options.
The two trials
The first, registered as a Phase 1b study at the NIH Clinical Center and now recruiting, examines tirzepatide’s dopaminergic effects in alcohol use disorder. It is a mechanism study, designed to see how the dual agonist acts on the dopamine reward system that drives drinking. It builds on a fast-growing line of work: preclinical studies show tirzepatide attenuates alcohol’s rewarding properties and its release of dopamine in the nucleus accumbens, and suppresses drinking and relapse-like behavior in rodents, while early human data, including a randomized trial of the related drug semaglutide, indicate that GLP-1 drugs reduce alcohol intake in people. Tirzepatide, which adds GIP agonism to GLP-1, is the next step along that line.
The second, sponsored by NIAAA, tests how suvorexant affects dopamine receptors in people with AUD and in healthy volunteers, using PET and MRI imaging during a supervised inpatient stay. The orexin system regulates arousal and also modulates reward and craving, which makes an approved orexin antagonist a second, non-traditional mechanism to interrogate. Like the tirzepatide study, it is built to answer how the drug acts on the reward system rather than whether it works at scale.
The pattern, and the difference
Both trials are federally funded, mechanism-first, and repurpose approved drugs, a metabolic drug and a sleep drug, toward the mesolimbic dopamine circuitry that underlies alcohol reward. That is the same shape as the OCD repurposing cluster: a neglected indication, stagnant pharmacology, and a revival driven by federal and academic science testing existing drugs on novel mechanistic hypotheses, because the commercial system did not. NIAAA is, in effect, assembling a mechanism portfolio for AUD on the gut-brain and reward axes.
The difference is commercial, and it is significant. OCD’s repurposing candidates are off-patent drugs with no commercial owner, which is why that revival lives entirely in academia. One of the AUD candidates is not. Tirzepatide is a blockbuster, on-patent drug owned by Eli Lilly, and the incretin class it belongs to is the most commercially valuable in medicine right now. If the AUD signal holds, GLP-1 for alcohol use disorder becomes the rare repurposing story that has both federal mechanism science behind it and a commercial owner with the resources and the incentive to develop the indication. That is what separates it from the OCD case, where the science can advance but the market has no reason to follow.
The caveats
Several cautions keep this in proportion. These are Phase 1 mechanism trials, designed to map how the drugs act on dopamine and reward, not to demonstrate that they treat alcohol use disorder. The headline is not a new AUD treatment; it is federal science working out why these drugs might help. The clinical evidence for GLP-1 drugs in AUD is promising but early, resting on one randomized trial and observational signals, with no GLP-1 approved for the indication and effect sizes and durability still unestablished. Tirzepatide as a dual agonist is a hypothesis extension, not a proven improvement. The framing of a coordinated federal portfolio overstates it; two mechanism trials in one cycle reflect convergent interest in the reward and gut-brain axes, not a master plan. And GLP-1 drugs carry their own complications in this population, from gastrointestinal tolerability to the unsettled question of whether any anti-craving effect is durable, to muscle-loss concerns in patients who may already be nutritionally compromised.
There is also the commercial caveat on the commercial point. A drug having an owner with means is not the same as that owner choosing to act. The GLP-1 makers have so far concentrated on the enormous metabolic and obesity markets, and whether any of them pursues an addiction indication while that market is still expanding is a separate decision from anything these federal trials test.
The frame
Alcohol use disorder is the addiction analog of OCD, a stuck, under-served indication being revived by federal repurposing of approved drugs on mechanisms outside the traditional playbook. But because one of those drugs belongs to the most valuable class in medicine, the AUD revival has something the OCD revival lacks: a plausible path to commercial development. The federal trials answer the mechanism question, how GLP-1 and orexin modulation act on the reward system. The commercial question, whether anyone turns that into an approved AUD medicine, depends on whether the owners of the era’s most lucrative drug class decide addiction is worth their attention while obesity is still paying. The mechanism science is moving. Whether the market follows is the open question, and it is a more answerable one here than in most neglected indications.